Interleukin Genetics Files to Raise up to $75M

Jan 06, 2010

NEW YORK (GenomeWeb News) – Interleukin Genetics has filed a shelf registration with the US Securities and Exchange Commission seeking to sell up to $75 million worth of stock or debt instruments.

The firm said in its SEC registration that it may offer shares of common stock and preferred stock, debt securities, warrants, or rights or contracts for any of those securities, either individually or in units.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Second One From Kite

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Worth the Price?

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Beyond Counting Tree Rings

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

This Week in Nature

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.

Main menu